Lung cancer arises from the cells that have grown abnormally and have multiplied to form a lump or tumor in the lungs. According to the WHO guidelines, Non-small cell lung cancers(NSCLS) refers to a subset of cancer types that account for approximately 80–85% of lung cancers. It can be classified histopathologically into Squamous cell carcinoma (SCC) and Non-Squamous NSCLC. Squamous cell carcinoma starts in early versions of squamous cells, which are flat cells that line the inside of the airways in the lungs. Non-Squamous NSCLC can be further categorized into adenocarcinoma, large cell carcinoma, etc. Adenocarcinoma is usually found in outer parts of the lung, whereas large cell carcinoma can appear in any part of the lung and tends to grow and spread rapidly. In the past several decades, the incidence of adenocarcinoma has increased greatly, and it replaced squamous cell carcinoma as the most incident type of NSCLC, and is differentiated very well. Genotyping studies have further revealed genetic/molecular abnormalities in accordance with tumor and mutation types.
The most common symptoms of lung cancer, including NSCLC, are persistent coughing; coughing blood; difficulty in breathing/breathlessness; hoarseness wheezing, and others. This condition is more common in males as compared to females.
The Non-Small Cell Lung Cancer market report covers emerging drugs, current treatment practices, Non-Small Cell Lung Cancer market share of the individual therapies, current and forecasted Non-Small Cell Lung Cancer Market Size from 2017 to 2030 segmented by seven major markets. The report also provides detailed current Non-Small Cell Lung Cancer treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Non-Small Cell Lung Cancer Market Key Facts
In the US, the age-adjusted incidence of NSCLC is 47.2 per 100,000 individuals and is most frequently diagnosed among people between 65 and 74 years old (SEER).
According to the American Cancer Society, the estimated incidence of lung cancer in the US for 2018 are about 234,030 new cases in which 121,680 are men and 112,350 are women.
According to the WHO, among the subtypes of NSCLC, squamous cell carcinoma accounts for 25–30% cases of lung cancers, adenocarcinoma accounts for 40% cases whereas large cell carcinoma accounts for 10–15%.
Large population-based studies in Western countries have indicated that the overall 1-year survival rate of NSCLC is 30–46% and 5-year survival rate is around 19%, respectively. Whereas, in the advanced stage (IIIB/IV), the 5-year survival rate is only 5–6%.
Visit For Sample Pages:
Key Benefits of Non-Small Cell Lung Cancer Market Report
Non-Small Cell Lung Cancer market report provides an in-depth analysis of Non-Small Cell Lung Cancer Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.
The Non-Small Cell Lung Cancer market report will help in developing business strategies by understanding the Non-Small Cell Lung Cancer Market trends & developments, key players and future market competition that will shape and drive the Non-Small Cell Lung Cancer market in the upcoming years.
The Non-Small Cell Lung Cancer market report covers Non-Small Cell Lung Cancer current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
The report provides a detailed assessment of the Non-Small Cell Lung Cancer market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
The Non-Small Cell Lung Cancer market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Non-Small Cell Lung Cancer market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The report gives a thorough detail of Non-Small Cell Lung Cancer market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
The Non-Small Cell Lung Cancer epidemiology section covers insights about historical and current Non-Small Cell Lung Cancer patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The Non-Small Cell Lung Cancer Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Non-Small Cell Lung Cancer market or expected to get launched in the market during the study period. The analysis covers Non-Small Cell Lung Cancer market uptake by drugs; patient uptake by therapies; and sales of each drug.
Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The current treatment options include surgery, radiation therapy, chemotherapy, targeted therapy, immune checkpoint inhibitors, or some combination of these, depending on the type of cancer, stage of the disease, and overall health as well as the age of the patient.
Major players, such as Novartis, BeiGene, Transgene, Heat Biologics, Bristol-Myers Squibb, Merck, Achilles Therapeutics, Amgen, Mersana, Turning Point Therapeutics, Xcovery, Spectrum Pharmaceuticals, and others are involved in developing therapies for Non-Small Cell Lung Cancer.
Drugs, such as Tislelizumab (BeiGene), Capmatinib (Novartis), TG4010 (Transgene), HS-110 (Heat Biologics), XMT-1536 (Mersana), Plinabulin (BeyondSpring Pharma), Tepotinib (Merck), Capmatinib (Novartis / Incyte Corporation), Poziotinib (Spectrum Pharmaceuticals) IO102 (IO Biotech), and others are being developed as the highly effective therapies for Non-Small Cell Lung Cancer.
Table of Contents
1. Key Insights
2. Executive Summary
3. Non-Small Cell Lung Cancer Competitive Intelligence Analysis
4. Non-Small Cell Lung Cancer Market Overview at a Glance
5. Non-Small Cell Lung Cancer Disease Background and Overview
6. Non-Small Cell Lung Cancer Patient Journey
7. Non-Small Cell Lung Cancer Epidemiology and Patient Population
8. Non-Small Cell Lung Cancer Treatment Algorithm, Current Treatment, and Medical Practices
9. Non-Small Cell Lung Cancer Unmet Needs
10. Key Endpoints of Non-Small Cell Lung Cancer Treatment
11. Non-Small Cell Lung Cancer Marketed Products
12. Non-Small Cell Lung Cancer Emerging Therapies
13. Non-Small Cell Lung Cancer Seven Major Market Analysis
14. Attribute Analysis
15. Non-Small Cell Lung Cancer Market Outlook (7 major markets)
16. Non-Small Cell Lung Cancer Access and Reimbursement Overview
17. KOL Views on the Non-Small Cell Lung Cancer Market.
18. Non-Small Cell Lung Cancer Market Drivers
19. Non-Small Cell Lung Cancer Market Barriers
21. DelveInsight Capabilities
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Address:304 S. Jones Blvd #2432
State: New York
Country: United States